Dashboard
Manage Tickers

RAPTRAPT Therapeutics, Inc.

Nasdaq rapt.com


$ 4.25 $ 0.25 (6.13 %)    

Wednesday, 15-May-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 4.245
$ 4.13
$ 4.23 x 400
$ 4.25 x 191
$ 4.06 - $ 4.28
$ 3.98 - $ 27.35
1,205,772
na
163.96M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 12-11-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wolfe-research-downgrades-rapt-therapeutics-to-peer-perform
Wolfe Research Downgrades RAPT Therapeutic...
05/14/2024 12:01:08

Wolfe Research analyst Andy Chen downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform.

barclays-downgrades-rapt-therapeutics-to-equal-weight-lowers-price-target-to-4
Barclays Downgrades RAPT Therapeutics to E...
05/10/2024 13:21:00

Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and lowers the price t...

guggenheim-downgrades-rapt-therapeutics-to-neutral
Guggenheim Downgrades RAPT Therapeutics to...
05/10/2024 10:29:15

Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

whats-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday
What's Going On With Dermatitis-Focused RA...
05/09/2024 18:12:49

RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to li...

why-duolingo-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Duolingo Shares Are Trading Lower By A...
05/09/2024 17:57:05

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

rapt-therapeutics-q1-eps-079-beats-081-estimate
RAPT Therapeutics Q1 EPS $(0.79) Beats $(0...
05/09/2024 13:01:31

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-neutral-on-rapt-therapeutics
HC Wainwright & Co. Reiterates Neutral on ...
04/10/2024 10:19:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

rapt-therapeutics-highlights-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head-and-neck-cancer-patients
RAPT Therapeutics Highlights Results From ...
04/09/2024 16:01:38

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% i...

jp-morgan-maintains-neutral-on-rapt-therapeutics-lowers-price-target-to-13
JP Morgan Maintains Neutral on RAPT Therap...
03/27/2024 14:44:03

JP Morgan analyst Anupam Rama maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $15 ...

rapt-therapeutics-q4-earnings-insights
RAPT Therapeutics: Q4 Earnings Insights
03/07/2024 14:25:06

rapt-therapeutics-q4-eps-080-beats-086-estimate-cash-balance-of-1589m-as-of-december-31-2023
RAPT Therapeutics Q4 EPS $(0.80) Beats $(0...
03/07/2024 13:06:20

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0...

rapt-therapeutics-announces-multiple-late-breaking-presentations-at-the-upcoming-american-association-for-cancer-research-annual-meeting
RAPT Therapeutics Announces Multiple Late-...
03/05/2024 21:34:13

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developi...

ubs-downgrades-rapt-therapeutics-to-neutral-lowers-price-target-to-10
UBS Downgrades RAPT Therapeutics to Neutra...
02/22/2024 12:37:11

UBS analyst Eliana Merle downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral and lowers the price target from $61...

rivian-automotive-reports-q4-loss-joins-etsy-lucid-group-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Rivian Automotive Reports Q4 Loss, Joins E...
02/22/2024 10:28:00

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.

whats-going-on-with-rapt-therapeutics-stock-on-wednesday
What's Going On With RAPT Therapeutics Sto...
02/21/2024 19:04:57

Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma...

why-international-flavors--fragrances-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why International Flavors & Fragrances Sha...
02/21/2024 18:50:15

Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported m...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
02/21/2024 17:31:07

correction-rapt-therapeutics-shares-are-trading-higher
CORRECTION: RAPT Therapeutics shares are t...
02/21/2024 16:39:55

leerink-partners-downgrades-rapt-therapeutics-to-market-perform-announces-10-price-target
Leerink Partners Downgrades RAPT Therapeut...
02/21/2024 12:21:16

Leerink Partners analyst Thomas Smith downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Market Perform and annou...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION